Stay updated with breaking news from Selecta Imm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced the completion of...
/PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced the completion of...
STOCKHOLM, Dec. 1, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced the completion of enrolment for DISSOLVE
An Analysis Of The Gene Therapy Viral Vector Landscape By Kyle M. O’Neil and Brendan J. Wang, Back Bay Life Science Advisors Over the last five years, multiple gene therapies have been approved by regulatory agencies and a bolus of late-stage pipeline assets are approaching the market. As the first few gene therapies realize their potential as transformative treatments for the genetic rare diseases, the space is seen as a crucial part of growth for the biopharmaceutical industry. However, as the first gene therapies began to post early wins, several challenges have emerged. With these chall...
02.08.21 -- Business Of Biotech Introduces The Cell And Gene Series - New Episodes Out Now! Business of Biotech and Life Science Connect. As a member of the Life Science Connect community you have access to content beyond our weekly newsletters, including our podcast series. Don’t forget to subscribe so that you never miss an episode! On the latest episode of Business of Biotech, Lineage Cell Therapeutics CEO, Brian Culley, explains how he kept the company's programs for OpRegen® (dry AMD with GA) and OPC1 (acute spinal cord injury) running on time despite the disruptions...